Patents by Inventor Anil Kumar Padyana

Anil Kumar Padyana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11957680
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase modulators and use thereof
    Patent number: 11872225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20230226055
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11590132
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 28, 2023
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20220395503
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 15, 2022
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase modulators and use thereof
    Patent number: 11464775
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 11, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE MODULATORS AND USE THEREOF
    Publication number: 20220233541
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11364240
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11040036
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: June 22, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210130371
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210077490
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE MODULATORS AND USE THEREOF
    Publication number: 20200206225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: July 2, 2020
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20200207785
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: August 15, 2018
    Publication date: July 2, 2020
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Inhibitors of leukotriene production
    Patent number: 9403830
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: August 2, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Steven Richard Brunette, Michael Jason Burke, Thomas Martin Kirrane, Jr., Chuk Chui Man, Daniel Richard Marshall, Anil Kumar Padyana, Hossein Razavi, Robert Sibley, Lana Louise Smith Keenan, Roger John Snow, Ronald John Sorcek, Hidenori Takahashi, Steven John Taylor, Michael Robert Turner, Erick Richard Roush Young, Qiang Zhang, Yunlong Zhang, Renee M. Zindell
  • Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
    Patent number: 9139567
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 22, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alexander Heim-Riether, Anil Kumar Padyana, Shuang Liang, Steven John Taylor, Qiang Zhang
  • Benzodioxane inhibitors of leukotriene production
    Patent number: 9133146
    Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: September 15, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Michael J. Burke, Thomas Martin Kirrane, Jr., Matthew Russell Netherton, Anil Kumar Padyana, Lana Louise Smith Keenan, Hidenori Takahashi, Michael Robert Turner, Qiang Zhang, Qing Zhang
  • ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
    Publication number: 20140221373
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Application
    Filed: July 17, 2012
    Publication date: August 7, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Alexander Heim-Riether, Anil Kumar Padyana, Shuang Liang, Steven John Taylor, Qiang Zhang
  • INHIBITORS OF LEUKOTRIENE PRODUCTION
    Publication number: 20140031339
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Asitha ABEYWARDANE, Steven Richard BRUNETTE, Michael Jason BURKE, Thomas Martin KIRRANE, JR., Chuk Chui MAN, Daniel Richard MARSHALL, Anil Kumar PADYANA, Hossein RAZAVI, Robert SIBLEY, Lana Louise SMITH KEENAN, Roger John SNOW, Ronald John SORCEK, Hidenori TAKAHASHI, Steven John TAYLOR, Michael Robert TURNER, Erick Richard Roush YOUNG, Qiang ZHANG, Yunlong ZHANG, Renee M. ZINDELL
  • BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION
    Publication number: 20130345195
    Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 26, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Asitha ABEYWARDANE, Michael J. BURKE, Thomas Martin KIRRANE, Matthew Russell NETHERTON, Anil Kumar PADYANA, Lana Louise SMITH KEENAN, Hidenori TAKAHASHI, Michael Robert TURNER, QIANG ZHANG, Qing ZHANG
  • Benzodioxane inhibitors of leukotriene production
    Patent number: 8551982
    Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Michael J. Burke, Thomas Martin Kirrane, Matthew Russell Netherton, Anil Kumar Padyana, Lana Louise Smith Keenan, Hidenori Takahashi, Michael Robert Turner, Qiang Zhang, Qing Zhang